ReviewThe Egyptian journal of medical human genetics2022
The potential application of probiotics for the prevention and treatment of COVID-19.
Review in The Egyptian journal of medical human genetics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Promising protective treatment potential of endophytic bacteriumJournal of Zhejiang University. Science. B · 2025Article
- Article
- Unveiling the antibacterial action of ambroxol against Staphylococcus aureus bacteria: in vitro, in vivo, and in silico investigation.BMC microbiology · 2024Article
- Hesperidin Nanoformulation: A Potential Strategy for Reducing Doxorubicin-Induced Renal Damage via the Sirt-1/HIF1-α/VEGF/NF-κB Signaling Cascade.Pharmaceuticals (Basel, Switzerland) · 2024Article
- Next-generation probiotics: the upcoming biotherapeutics.Molecular biology reports · 2024Review
- Role of GABA pathway in motor and non-motor symptoms in Parkinson's disease: a bidirectional circuit.European journal of medical research · 2024Review
- Outlining the Phytoconstituents of Greek Clover Herb Extract and Assessment of Its Effect against Foodborne Infections Caused byPharmaceuticals (Basel, Switzerland) · 2024Article
- Role of fenofibrate in multiple sclerosis.European journal of medical research · 2024Review
- Plausible Protective Role ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Celecoxib-Loaded Cubosomal Nanoparticles as a Therapeutic Approach forMicroorganisms · 2023Article
- Cholinergic dysfunction in COVID-19: frantic search and hoping for the best.Naunyn-Schmiedeberg's archives of pharmacology · 2023Review
- A perspective study of the possible impact of obeticholic acid against SARS-CoV-2 infection.Inflammopharmacology · 2023Review
- Is sitagliptin effective for SARS-CoV-2 infection: false or true prophecy?Inflammopharmacology · 2022Review
- Potential role of lipoxin in the management of COVID-19: a narrative review.Inflammopharmacology · 2022Review
- The role of berberine in Covid-19: potential adjunct therapy.Inflammopharmacology · 2022Review
- Ursolic acid and SARS-CoV-2 infection: a new horizon and perspective.Inflammopharmacology · 2022Review
- Traditional herbs against COVID-19: back to old weapons to combat the new pandemic.European journal of medical research · 2022Review
- Gut bacteria, bacteriophages, and probiotics: Tripartite mutualism to quench the SARS-CoV2 storm.Microbial pathogenesis · 2022Review
- Novel Exopolysaccharide from MarineMetabolites · 2022Article
- Dipyridamole and adenosinergic pathway in Covid-19: a juice or holy grail.The Egyptian journal of medical human genetics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Given the severe infection, poor prognosis, and the low number of available effective drugs, potential prevention and treatment strategies for COVID-19 need to be urgently developed. Main body: Herein, we present and discuss the possible protective and therapeutic mechanisms of human microbiota and probiotics based on the previous and recent findings. Microbiota and probiotics consist of mixed cultures of living microorganisms that can positively affect human health through their antiviral, antibacterial, anti-inflammatory, and immunomodulatory effect. In the current study, we address the promising advantages of microbiota and probiotics in decreasing the risk of COVID-19. Conclusions: Thus, we recommend further studies be conducted for assessing and evaluating the capability of these microbes in the battle against COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.